Effect of Nafamostat on Postreperfusion Syndrome (PRS)

• Status: Completed
• Trial end date: 2010-04-01
• Target enrollment: 0
• Participant gender: All

Summary

This study intends to see the effect of nafamostat on the attenuation of postreperfusion syndrome (PRS) that frequently occurs during liver transplantation.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Seoul National University Hospital
• Treatments: Nafamostat

Criteria

Inclusion Criteria:

• >= 18 year old scheduled to undergo liver transplantation

Exclusion Criteria:

• Previous history of pulmonary, cardiovascular, or renal disease

• Previous history of allergic reactions to nafamostat